Key clinical trials of lifestyle and pharmacological interventions for NASH/MASH: histological and fibrosis outcomes.
| Author/Year/Ref | Methods | Key findings | Conclusion |
|---|---|---|---|
| Vilar-Gomez et al., 2015 [14] | Prospective, 52-week lifestyle-intervention cohort of 293 adults with biopsy-proven NASH; 261 had paired liver biopsies. Participants received dietary and physical-activity counselling, and histological change was related to achieved weight loss. | Overall, 25% achieved NASH resolution, 47% had a reduction in NAFLD Activity Score, and 19% had fibrosis regression. Among patients losing ≥ 10% of body weight, all had a reduction in activity score, 90% achieved NASH resolution, and 45% had fibrosis regression. | Lifestyle-induced weight loss was associated with graded histological benefit; 7%–10% reduction in body weight was associated with meaningful histological improvement, whereas weight loss ≥ 10% may induce higher rates of NASH resolution and fibrosis regression. |
| Newsome et al., 2021 [15] | Double-blind, phase 2 trial of 320 adults with biopsy-confirmed NASH and F1–F3 fibrosis, randomly assigned to once-daily s.c. semaglutide 0.1 mg, 0.2 mg, or 0.4 mg, or placebo, for 72 weeks. Primary histological analyses focused on participants with F2–F3 fibrosis. | NASH resolution without fibrosis worsening occurred in 59% with semaglutide 0.4 mg versus 17% with placebo. Fibrosis improvement occurred in 43% versus 33%, a non-significant difference. Mean weight loss was 13% versus 1%, with gastrointestinal adverse events more frequent on semaglutide. | Semaglutide substantially increased NASH resolution but did not significantly improve fibrosis, indicating a strong effect on disease activity without established antifibrotic efficacy in this trial. |
| Harrison et al., 2024 [16] | Ongoing, double-blind, phase 3 trial in 966 adults with biopsy-confirmed NASH and F1B–F3 fibrosis, randomly assigned 1:1:1 to oral resmetirom 80 mg, resmetirom 100 mg, or placebo once daily. Dual primary histological endpoints were assessed at 52 weeks. | NASH resolution without fibrosis worsening occurred in 25.9% and 29.9% with resmetirom 80 mg and 100 mg, respectively, versus 9.7% with placebo. Fibrosis improvement by at least one stage without worsening of activity score occurred in 24.2% and 25.9%, respectively, vs. 14.2% with placebo; LDL cholesterol also fell significantly. | Both resmetirom doses improved steatohepatitis resolution and fibrosis compared with placebo, supporting liver-directed thyroid hormone receptor-β agonism as an effective disease-modifying strategy. |
| Sanyal et al., 2024 [17] | In this 48-week phase 2 trial, adults with biopsy-proven MASH and fibrosis stage F1–F3 were randomly assigned in a 1:1:1:1 ratio to receive once-weekly s.c. survodutide at 2.4, 4.8, or 6.0 mg, or placebo. The trial included a 24-week rapid dose-escalation phase followed by a 24-week maintenance phase. The primary endpoint was histologic improvement in MASH without worsening of fibrosis. Secondary endpoints included ≥ 30% reduction in LFC and biopsy-proven fibrosis improvement of ≥ 1 stage. | Among 293 randomized participants who received ≥ 1 dose of study drug, MASH improvement without fibrosis worsening occurred in 47%, 62%, and 43% of those receiving survodutide 2.4, 4.8, and 6.0 mg, respectively, vs. 14% with placebo (P < 0.001 for the quadratic dose–response model). LFC fell by ≥ 30% in 63%, 67%, 57% and 14% of participants, respectively, and fibrosis improved by ≥ 1 stage in 34%, 36%, 34% and 22%. Nausea, diarrhea, and vomiting were more common with survodutide than placebo (66% vs. 23%, 49% vs. 23%, and 41% vs. 4%, respectively), whereas serious adverse events were similar between groups. | Survodutide improved MASH without worsening fibrosis more effectively than placebo, supporting further evaluation in phase 3 trials. |
| Sanyal et al., 2025 [18] | Ongoing multicenter, randomized, double-blind, placebo-controlled phase 3 trial of 1,197 adults with biopsy-defined MASH and F2–F3 fibrosis, assigned 2:1 to once-weekly s.c. semaglutide 2.4 mg or placebo for 240 weeks. The planned week-72 interim analysis included the first 800 participants. | MASH resolution without fibrosis worsening occurred in 62.9% with semaglutide versus 34.3% with placebo. Fibrosis improvement without worsening of MASH occurred in 36.8% versus 22.4%, and combined MASH resolution and fibrosis improvement in 32.7% versus 16.1%. Mean body-weight change was −10.5% versus −2.0%. | Once-weekly semaglutide 2.4 mg improved both steatohepatitis and fibrosis outcomes in patients with MASH and moderate or advanced fibrosis, although longer-term follow-up remains ongoing. |
LDL: low-density lipoprotein; LFC: liver fat content; MASH: metabolic dysfunction-associated steatohepatitis; NAFLD: nonalcoholic fatty liver disease; NASH: nonalcoholic steatohepatitis; s.c.: subcutaneous.